Literature DB >> 12750283

Fanconi anemia gene mutations in young-onset pancreatic cancer.

Michiel S van der Heijden1, Charles J Yeo, Ralph H Hruban, Scott E Kern.   

Abstract

Genes of the Fanconi complementation groups [Fanconi anemia (FA) genes] are suggested to be involved in homologous DNA recombination and produce FA when two allelic mutations are inherited. BRCA2 is an FA gene and additionally conveys an inherited risk for breast, ovarian, and pancreatic cancer for individuals carrying a single mutated allele [N. G. Howlett et al., Science (Wash. DC), 297: 606-609, 2002]. Here we report inherited and somatic mutations of FANCC and FANCG present in young-onset pancreatic cancer. This may imply a general involvement of Fanconi genes with an inherited risk of cancer. The known hypersensitivity of Fanconi cells to mitomycin and other therapeutic agents [M. S. Sasaki, Nature (Lond.), 257: 501-503, 1975] suggests a therapeutic utility for a more complete characterization of the DNA repair defects and their causative genetic mutations in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750283

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  84 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

Review 2.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

Review 3.  Molecular pathogenesis of Fanconi anemia.

Authors:  Natalie Collins; Gary M Kupfer
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 4.  Fanconi anaemia: from a monogenic disease to sporadic cancer.

Authors:  Antonio Valeri; Sandra Martínez; José A Casado; Juan A Bueren
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

5.  Advances in counselling and surveillance of patients at risk for pancreatic cancer.

Authors:  Randall E Brand; Markus M Lerch; Wendy S Rubinstein; John P Neoptolemos; David C Whitcomb; Ralph H Hruban; Teresa A Brentnall; Henry T Lynch; Marcia I Canto
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

6.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

7.  FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.

Authors:  Chen Ling; Masamichi Ishiai; Abdullah Mahmood Ali; Annette L Medhurst; Kornelia Neveling; Reinhard Kalb; Zhijiang Yan; Yutong Xue; Anneke B Oostra; Arleen D Auerbach; Maureen E Hoatlin; Detlev Schindler; Hans Joenje; Johan P de Winter; Minoru Takata; Amom Ruhikanta Meetei; Weidong Wang
Journal:  EMBO J       Date:  2007-03-29       Impact factor: 11.598

Review 8.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

Review 9.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

Review 10.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.